HC Wainwright Forecasts MindWalk FY2031 Earnings

MindWalk Holdings Corp. (NASDAQ:HYFT) – Stock analysts at HC Wainwright issued their FY2031 earnings per share estimates for shares of MindWalk in a research report issued to clients and investors on Thursday, July 23rd. HC Wainwright analyst S. Ramakanth anticipates that the company will earn $0.13 per share for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for MindWalk’s current full-year earnings is ($0.17) per share.

Other analysts also recently issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. JonesTrading began coverage on shares of MindWalk in a report on Thursday, April 16th. They issued a “buy” rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, MindWalk currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

MindWalk Stock Down 18.1%

MindWalk stock opened at $1.18 on Friday. MindWalk has a 52-week low of $0.99 and a 52-week high of $3.25. The company has a current ratio of 3.74, a quick ratio of 3.64 and a debt-to-equity ratio of 0.21. The company’s fifty day simple moving average is $1.55. The stock has a market capitalization of $55.12 million, a P/E ratio of -5.36 and a beta of 0.83.

MindWalk (NASDAQ:HYFT) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). MindWalk had a negative return on equity of 84.79% and a negative net margin of 89.65%.The business had revenue of $3.03 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HYFT. Virtu Financial LLC purchased a new stake in shares of MindWalk in the fourth quarter valued at $51,000. Bridgeway Capital Management LLC purchased a new position in shares of MindWalk during the 4th quarter worth about $91,000. Bank of Montreal Can grew its holdings in MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after purchasing an additional 24,500 shares during the last quarter. XTX Topco Ltd grew its holdings in MindWalk by 118.6% during the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after purchasing an additional 44,331 shares during the last quarter. Finally, Jane Street Group LLC raised its position in MindWalk by 147.3% in the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after purchasing an additional 96,018 shares during the period. 6.70% of the stock is owned by hedge funds and other institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.